Core Viewpoint - The article discusses the recent approval of Eli Lilly's new drug eloralintide for clinical trials in China, aimed at treating obesity and related conditions, highlighting the competitive landscape in the GLP-1 drug market [4][6]. Group 1: Drug Approval and Clinical Trials - Eli Lilly's eloralintide injection has received clinical trial approval from China's National Medical Products Administration (NMPA) for treating obesity or overweight individuals with knee osteoarthritis pain [4]. - The company is advancing multiple Phase III clinical studies for eloralintide, targeting obesity, obstructive sleep apnea, and knee osteoarthritis, indicating a significant step in local research [6]. Group 2: Market Competition and Differentiation Strategies - The competition in the domestic semaglutide market is intensifying, with several biosimilars for type 2 diabetes and obesity either in Phase III trials or having received IND approval [6]. - In response to increasing "homogenization" pressure, companies are accelerating the search for differentiation strategies, including the development of oral formulations, extending half-lives, multi-target approaches to enhance efficacy, and exploring new sales and service models [8].